HLB Pharmaceutical Statistics

Total Valuation

HLB Pharmaceutical has a market cap or net worth of KRW 320.16 billion.

Market Cap	320.16B
Enterprise Value	n/a

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

HLB Pharmaceutical has 14.04 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	14.04M
Shares Change (YoY)	n/a
Shares Change (QoQ)	-0.70%
Owned by Insiders (%)	11.17%
Owned by Institutions (%)	4.01%
Float	8.15M

Valuation Ratios

The trailing PE ratio is 677.37.

PE Ratio	677.37
Forward PE	n/a
PS Ratio	8.75
PB Ratio	17.64
P/TBV Ratio	18.34
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.26, with a Debt / Equity ratio of 0.74.

Current Ratio	1.26
Quick Ratio	1.01
Debt / Equity	0.74
Debt / EBITDA	4.28
Debt / FCF	-301.34
Interest Coverage	1.21

Financial Efficiency

Return on equity (ROE) is 2.71% and return on invested capital (ROIC) is 3.23%.

Return on Equity (ROE)	2.71%
Return on Assets (ROA)	2.19%
Return on Capital (ROIC)	3.23%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.88
Inventory Turnover	3.27

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +64.19% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+64.19%
50-Day Moving Average	20,805.60
200-Day Moving Average	25,227.30
Relative Strength Index (RSI)	56.65
Average Volume (20 Days)	249,973

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, HLB Pharmaceutical had revenue of KRW 36.10 billion and earned 472.66 million in profits. Earnings per share was 34.13.

Revenue	36.10B
Gross Profit	18.04B
Operating Income	1.44B
Pretax Income	-123.03M
Net Income	472.66M
EBITDA	3.08B
EBIT	1.44B
Earnings Per Share (EPS)	34.13

Full Income Statement

Balance Sheet

The company has 15.16 billion in cash and 13.20 billion in debt, giving a net cash position of 1.96 billion or 139.93 per share.

Cash & Cash Equivalents	15.16B
Total Debt	13.20B
Net Cash	1.96B
Net Cash Per Share	139.93
Equity (Book Value)	17.90B
Book Value Per Share	1,292.83
Working Capital	5.93B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.35 billion and capital expenditures -1.40 billion, giving a free cash flow of -43.80 million.

Operating Cash Flow	1.35B
Capital Expenditures	-1.40B
Free Cash Flow	-43.80M
FCF Per Share	-3.12

Full Cash Flow Statement

Margins

Gross margin is 49.98%, with operating and profit margins of 3.99% and 1.31%.

Gross Margin	49.98%
Operating Margin	3.99%
Pretax Margin	-0.34%
Profit Margin	1.31%
EBITDA Margin	8.53%
EBIT Margin	3.99%
FCF Margin	n/a

Dividends & Yields

HLB Pharmaceutical does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.30%
Shareholder Yield	-2.30%
Earnings Yield	0.15%
FCF Yield	-0.01%

Stock Splits

The last stock split was on April 12, 2016. It was a forward split with a ratio of 1.5.

Last Split Date	Apr 12, 2016
Split Type	Forward
Split Ratio	1.5

Scores

HLB Pharmaceutical has an Altman Z-Score of 2.49. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.49
Piotroski F-Score	n/a